Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.36 Analyst target: $17.67 Upside: 648.73%
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. The company is headquartered in Palo Alto, California.
See the full interactive analysis & chart →Informational only — not investment advice.